Changes in neutrophil phenotype following the administration of CC-4047 (Actimid) to patients with multiple myeloma.
Matthew Streetly(King's College - North Carolina), Stephen Schey(University College Hospital), D. McCarthy(Queen Mary University of London), Robert J. Knight(University of California San Diego), Paul Fields(Adaptive Biotechnologies (United States)), M. G. Macey, K A Brown(Uniformed Services University of the Health Sciences)
Research Portal (King's College London)
January 1, 2003
Cited by 1
Related Papers
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age.
|Circulation|1991|392
Psychosocial risk factors for suicidality in children and adolescents
|European Child & Adolescent Psychiatry|2019|379
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315